Document:

<PAGE>

                                                                     Exhibit 4.1

                                 [FACE OF NOTE]

                        EOP OPERATING LIMITED PARTNERSHIP

                              8.10% Notes due 2010

No. 001                                                         Principal Amount
CUSIP No. 268766BN1                                                 $360,000,000

         UNLESS THIS NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION ("DTC"), TO THE ISSUER OR ITS
AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT AND ANY NOTE ISSUED IS
REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF DTC AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO
SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC, ANY
TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON
IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST
HEREIN.

         UNLESS AND UNTIL THIS NOTE IS EXCHANGED IN WHOLE OR IN PART FOR NOTES
IN CERTIFICATED FORM, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY DTC
TO A NOMINEE THEREOF OR BY A NOMINEE THEREOF OR BY A NOMINEE THEREOF TO DTC OR
ANOTHER NOMINEE OF DTC OR BY DTC OR ANY SUCH NOMINEE TO A SUCCESSOR OF DTC OR A
NOMINEE OF SUCH SUCCESSOR.

         THIS NOTE WILL BE ISSUED AND MAY BE TRANSFERRED ONLY IN MINIMUM
DENOMINATIONS OF $1,000 AND INTEGRAL MULTIPLES THEREOF.

         EOP Operating Limited Partnership, a Delaware limited partnership (the
"Issuer," which term includes any successor under the Indenture hereinafter
referred to), for value received, hereby promises to pay to Cede & Co. or
registered assigns, the principal sum of Three Hundred and Sixty Million Dollars
on August 1, 2010 (the "Stated Maturity Date"), (or any Redemption Date, as
defined on the reverse hereof) or any earlier date of acceleration of maturity,
(each such date being referred to as the "Maturity Date" with respect to the
principal repayable on such date) and to pay interest thereon from August 7,
2000 (or from the most recent Interest Payment Date (as defined below) to which
interest has been paid or duly provided for), semiannually in arrears on
February 1 and August 1 of each year, commencing on February 1, 2001 (each, an
"Interest Payment Date"), and on the Maturity Date, at a rate of 8.10% per
annum, until payment of said principal sum has been made or duly provided for.
Interest on this Note will be computed on the basis of a 360-day year of twelve
30-day months.

<PAGE>

         The interest so payable and punctually paid or duly provided for on an
Interest Payment Date will, subject to certain exceptions described below, be
paid to the Holder in whose name this Note (or one or more predecessor Notes) is
registered at the close of business on the "Regular Record Date" for such
payment, which will be July 15 or January 15 (regardless of whether such day is
a Business Day (as defined below)) next preceding such Interest Payment Date.
Any interest not so punctually paid or duly provided for on an Interest Payment
Date ("Defaulted Interest") shall forthwith cease to be payable to the Holder on
such Regular Record Date, and shall be paid to the Holder in whose name this
Note (or one or more predecessor Notes) is registered at the close of business
on a special record date (the "Special Record Date") for the payment of such
Defaulted Interest to be fixed by the Trustee hereinafter referred to, notice
whereof shall be given to the Holder of this Note by the Trustee not less than
10 calendar days prior to such Special Record Date or may be paid at any time in
any other lawful manner, all as more fully provided for in the Indenture.

         The principal of and Make-Whole Amount, if any, with respect to this
Note payable on the Maturity Date will be paid against presentation and
surrender of this Note at the office or agency of the Issuer maintained for that
purpose in Boston, Massachusetts with a drop facility maintained in New York,
New York. The Issuer hereby initially designates the Corporate Trust Office of
the Trustee in Boston, Massachusetts as the office to be maintained by it where
Notes may be presented for payment, registration of transfer, or exchange and
where notices or demands to or upon the Issuer in respect of the Notes or the
Indenture may be served.

         Interest payable on this Note on any Interest Payment Date and on the
Maturity Date, as the case may be, will be the amount of interest accrued during
the applicable Interest Period (as defined below).

         An "Interest Period" is each period from and including the immediately
preceding Interest Payment Date (or from and including August 7, 2000 in the
case of the initial Interest Period) to but excluding the applicable Interest
Payment Date or the Maturity Date, as the case may be. If any Interest Payment
Date or Maturity Date falls on a day that is not a Business Day, principal,
Make-Whole Amount, if any, and interest payable on such date will be paid on the
succeeding Business Day with the same force and effect as if it were paid on the
date such payment was due, and no interest will accrue on the amount so payable
for the period from and after such date to such succeeding Business Day.
"Business Day" means any day, other than a Saturday or a Sunday, on which
banking institutions in New York, New York and Boston, Massachusetts are not
required or authorized by law or executive order to close.

         Payments of principal, Make-Whole Amount, if any, and interest in
respect of this Note will be made by U.S. dollar check or by wire transfer (such
a wire transfer to be made only to a Holder of an aggregate principal amount of
Notes in excess of $10,000,000, and only if such Holder shall have furnished
wire instructions in writing to the Trustee no later than 15 days prior to the
relevant payment date and acknowledged that a wire transfer fee shall be
payable) of immediately available funds in such coin or currency of the United
States of America as at the time of payment is legal tender for the payment of
public and private debts.

<PAGE>

         Reference is made to the further provisions of this Note set forth on
the reverse hereof. Such further provisions shall for all purposes have the same
effect as though fully set forth at this place. Capitalized terms used herein,
including on the reverse hereof, and not defined herein or on the reverse hereof
shall have the respective meanings given to such terms in the Indenture.

         This Note shall not be entitled to the benefits of the Indenture or be
valid or become obligatory for any purpose until the certificate of
authentication hereon shall have been signed by the Trustee.

<PAGE>

         IN WITNESS WHEREOF, the Issuer has caused this Note to be signed
manually or by facsimile by a duly authorized officer of the General Partner.

Dated:  August 7, 2000     EOP OPERATING LIMITED PARTNERSHIP,
                           as Issuer

                               By:  EQUITY OFFICE PROPERTIES TRUST, not
                                    individually but as Managing General Partner

                               By:  /s/ RICHARD D. KINCAID
                                  ----------------------------------------------
                                        Richard D. Kincaid
                                        Its: Executive Vice President and
                                             Chief Financial Officer

                               ATTEST:

                               By:  /s/ STANLEY M. STEVENS
                                  ----------------------------------------------
                                        Stanley M. Stevens
                                        Its: Executive Vice President, Chief
                                             Legal Counsel and Secretary

                     TRUSTEE'S CERTIFICATE OF AUTHENTICATION

This is one of the Notes of the series designated herein referred to in the
within-mentioned Indenture.

Dated:  August 7, 2000     STATE STREET BANK AND TRUST COMPANY,
                           as Trustee

                               By:  /s/ DONALD E. SMITH
                                  ---------------------------------------------
                                     Authorized Officer

<PAGE>

                                [REVERSE OF NOTE]

                        EOP OPERATING LIMITED PARTNERSHIP

                              8.10% Notes due 2010

         This Note is one of a duly authorized issue of senior Notes of the
Issuer (hereinafter called the "Notes") of the series hereinafter specified, all
issued or to be issued under and pursuant to an Indenture dated as of September
2, 1997 (as amended, the "Indenture"), duly executed and delivered by the Issuer
to State Street Bank and Trust Company, as Trustee (herein called the "Trustee,"
which term includes any successor trustee under the Indenture with respect to
the series of Notes of which this Note is a part), to which Indenture and all
indentures supplemental thereto reference is hereby made for a description of
the rights, limitations of rights, obligations, duties, and immunities
thereunder of the Trustee, the Issuer, and the Holders of the Notes, and of the
terms upon which the Notes are, and are to be, authenticated and delivered. The
Notes may be issued in one or more series, which different series may be issued
in various aggregate principal amounts, may mature at different times, may bear
interest (if any) at different rates, may be subject to different redemption
provisions (if any), and may otherwise vary as provided in the Indenture. This
Note is one of a series designated as the 8.10% Notes due 2010 of the Issuer
(the "Notes"), limited in aggregate principal amount to $360,000,000, subject to
the provisions in the Indenture.

         In case an Event of Default with respect to the Notes shall have
occurred and be continuing, the principal hereof and Make-Whole Amount (if any)
may be declared, and upon such declaration shall become, due and payable, in the
manner, with the effect, and subject to the conditions provided in the
Indenture.

         The Issuer may redeem this Note, at any time in whole or from time to
time in part, at the election of the Issuer, at a redemption price equal to the
sum of (i) the principal amount being redeemed plus accrued interest thereon to
the date fixed for redemption (the "Redemption Date") and (ii) the Make-Whole
Amount with respect hereto (the "Redemption Price"); provided, however, that
interest installments due on an Interest Payment Date which is on or prior to
the Redemption Date will be payable to the Holder hereof (or one or more
predecessor Notes) as of the close of business on the Record Date preceding such
Interest Payment Date. If notice has been given as provided in the Indenture and
funds for the redemption of this Note or any part thereof called for redemption
shall have been made available on the Redemption Date, this Note or such part
thereof will cease to bear interest on the Redemption Date referred to in such
notice and the only right of the Holder will be to receive payment of the
Redemption Price. Notice of any optional redemption of any Notes will be given
to the holder hereof (in accordance with the provisions of the Indenture), not
more than 60 nor less than 30 days prior to the Redemption Date. In the event of
redemption of this Note in part only, a new Note of like tenor for the
unredeemed portion hereof and otherwise having the same terms and provisions as
this Note shall be issued by the Issuer in the name of the Holder hereof upon
the presentation and surrender hereof.

<PAGE>

         The Indenture contains provisions for defeasance of (i) the entire
indebtedness of the Notes or (ii) certain covenants and Events of Default with
respect to the Notes, in each case upon compliance with certain conditions set
forth therein, which provisions apply to the Notes.

         The Indenture contains provisions permitting the Issuer and the
Trustee, with the consent of the Holders of not less than a majority of the
aggregate principal amount of the Notes at the time Outstanding of all series to
be affected (voting as one class), evidenced as provided in the Indenture, to
execute supplemental indentures adding any provisions to or changing in any
manner or eliminating any of the provisions of the Indenture or of any
supplemental indenture or modifying in any manner the rights of the Holders of
the Notes of each series; provided, however, that no such supplemental indenture
shall, without the consent of the Holder of each Note at the time Outstanding so
affected, (i) change the final maturity of any Note, or reduce the principal
amount thereof or any premium or Make-Whole Amount thereon, if any, or reduce
the rate or extend the time of payment of any interest thereon, or impair or
affect the rights of' any Holder to institute suit for the payment on any Note,
or (ii) reduce the percentage in principal amount of Outstanding Notes, the
Holders of which are required to consent to any such supplemental indenture, or
(iii) reduce the percentage in principal amount of Outstanding Notes, the
Holders of which are required to consent to any waiver of compliance with
certain provisions of the Indenture or any waiver of certain defaults
thereunder. It is also provided in the Indenture that, with respect to certain
defaults or Events of Default regarding the Notes of any series, the Holders of
a majority in aggregate principal amount Outstanding of the Notes of such series
(or, in the case of certain defaults or Events of Default, all series of Notes)
may on behalf of the Holders of all the Notes of such series (or all of the
Notes, as the case may be) waive any such past default or Event of Default and
its consequences, prior to any declaration accelerating the maturity of such
Notes, or, subject to certain conditions, may rescind a declaration of
acceleration and its consequences with respect to such Notes. The preceding
sentence shall not, however, apply to a default in or Event of Default relating
to the payment of the principal of or premium or Make-Whole Amount, if any, or
interest on any of the Notes or in respect of a covenant or provision contained
in the Indenture that cannot be modified or amended without the consent of the
Holders of each Note at the time Outstanding affected thereby. Any such consent
or waiver by the Holder of this Note (unless revoked as provided in the
Indenture) shall be conclusive and binding upon such Holder and upon all future
Holders and owners of this Note and any Notes that may be issued in exchange or
substitution herefor, irrespective of whether or not any notation thereof is
made upon this Note or such other Notes.

         No reference herein to the Indenture and no provision of this Note or
of the Indenture shall alter or impair the obligation of the Issuer, which is
absolute and unconditional, to pay the principal of and any Make-Whole Amount
and interest on this Note in the manner, at the respective times, at the rate
and in the coin or currency herein prescribed.

         This Note is issuable only in registered form without coupons in
denominations of U.S. $1,000 and integral multiples thereof. Notes may be
exchanged for a like aggregate

<PAGE>

principal amount of Notes of this series of other authorized denominations at
the office or agency of the Issuer in Boston, Massachusetts, in the manner and
subject to the limitations provided herein and in the Indenture, but without the
payment of any service charge except for any tax or other governmental charge
imposed in connection therewith.

         Upon due presentment for registration of transfer of this Note at the
office or agency of the Issuer in Boston, Massachusetts, one or more new Notes
of authorized denominations in an equal aggregate principal amount will be
issued to the transferee in exchange therefor, subject to the limitations
provided in the Indenture, but without the payment of any service charge except
for any tax or other governmental charge imposed in connection therewith.

         This Note is not subject to a sinking fund requirement.

         No recourse under or upon any obligation, covenant or agreement
contained in the Indenture, or any Note, or because of any indebtedness
evidenced hereby or thereby (including, without limitation, any obligation or
indebtedness relating to the principal of, or premium or Make-Whole Amount, if
any, interest or any other amounts due, or claimed to be due, on this Note), or
for any claim based thereon or otherwise in respect thereof, shall be had (i)
against the General Partner or any other partner, or any Person which owns an
interest, directly or indirectly, in any partner, in the Issuer, or (ii) against
any promoter, as such, or against any past, present or future shareholder,
officer, trustee or partner, as such, of the Issuer or the General Partner or
any successor, either directly or through the Issuer or the General Partner or
any successor, under any rule of law, statute or constitutional provision or by
the enforcement of any assessment or by any legal or equitable proceeding or
otherwise, al such liability being expressly waived and released by the
acceptance hereof and as part of the consideration for the issue hereof.

         Prior to due presentation of this Note for registration of transfer,
the Issuer, the Trustee, and any authorized agent of the Issuer or the Trustee
may deem and treat the Person in whose name this Note is registered as the
absolute owner of the Note (whether or not this Note shall be overdue and
notwithstanding any notation of ownership or other writing hereon), for the
purpose of receiving payment of, or on account of, the principal hereof and
Make-Whole Amount, if any, and subject to the provisions herein and on the face
hereof, interest hereon, and for all other purposes, and neither the Issuer nor
the Trustee nor any authorized agent of the Issuer or the Trustee shall be
affected by any notice to the contrary, except as required by law.

         THE INDENTURE AND THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK, UNITED STATES OF AMERICA
WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS.

<PAGE>

                   ASSIGNMENT FORM AND CERTIFICATE OF TRANSFER

   To assign this Note fill in the form below:

   (I) or (we) assign and transfer this Note to

        (Insert assignee's social security or tax identification number, if any)

                          (Print or type assignee's name, address and zip code)

         Your signature:

              (Sign exactly as your name appears on the other side of this Note)

         Date:

         Signature Guarantee:*

-------------
* Signature must be guaranteed by a commercial bank, trust company or member
firm or a major stock exchange.<PAGE>

[LOGO]

                           CONTRACT MANUFACTURING AGREEMENT

THIS CONTRACT MANUFACTURING AGREEMENT (the "Agreement") is made and entered into
as of March 17, 2000 ("Date of Agreement"), by and between:

Chiron S.p.A., with its registered offices at Via Fiorentina 1, 53100 Siena,
Italy, hereafter referred to as "Chiron",

and

SynCo Bio Partners B.V., with its registered offices at Paasheuvelweg 30, 1105
BJ Amsterdam Zuidoost, The Netherlands, hereafter referred to as the "SynCo".

BACKGROUND

-      Chiron has developed or is developing a broad line of novel adult and
       pediatric vaccines for viral and bacterial infectious diseases;

-      SynCo operates a manufacturing plant in Amsterdam, The Netherlands;

-      Chiron wishes to contract with SynCo to provide services related to the
       production of certain vaccines or intermediate products in the Plant, in
       quantities and at times to be separately agreed upon between Parties.
       SynCo is willing to use its personnel, expertise and facilities to
       discharge such contract manufacturing tasks and to provide such services,
       assistance, advice and consulting as Chiron may request from time to
       time.

NOW, THEREFORE, in consideration of the premises, the mutual covenants, terms
and conditions hereinafter set forth, THE PARTIES AGREE AS FOLLOWS:

<PAGE>

ARTICLE 1 - DEFINITIONS

For the purpose of this Agreement the following terms shall be defined as
follows:

1.1.   "Affiliate" means: with respect to either Party, any company, entity,
joint venture or similar business arrangement which is controlled by,
controlling or under common control with such Party, and shall include without
limitation any company fifty percent or more of whose voting stock or
participating profit interest is owned or controlled, directly or indirectly, by
such Party, and any company which owns or controls, directly or indirectly,
fifty percent or more of such Party.

1.2.   "BPRs" means: the batch production records and other documents providing
the manufacturing history of a batch of Product.

1.3.   "Confidential Information" means: (a) all information disclosed by either
Party in writing and designated confidential, (b) all information disclosed
orally that is confirmed in writing and designated confidential within thirty
(30) days after such disclosure, (c) all information relating to Patents, (d)
all Specifications, (e) all other Technology, and (f) all other information
relating to the manufacture of the Products, whether such information is
provided to SynCo by Chiron hereunder or otherwise.

1.4.   "GMP" means: European Good Manufacturing Practices for Medicinal Products
as in effect at the time of manufacture of any Product supplied to Chiron
hereunder.

1.5.   "Material" means: the working cell banks and specific reagents as
required for the manufacture of the Products in accordance with the relevant
Specifications. Commercially available raw materials are excluded.

1.6.   "Parties" and "Party" means: SynCo and Chiron and SynCo or Chiron,
respectively, as the context may require.

1.7.   "Patents" means all Patents owned by or licensed (with a right to
sublicense) to Chiron or any of its Affiliates claiming Technology.

1.8.   "Plant" means: SynCo's facility located at Paasheuvelweg 30, 1105 BJ
Amsterdam Zuidoost, The Netherlands.

1.9.   "Product" or "Products means: any or all of the vaccine products or
intermediate products thereof listed on Exhibit B.

1.10.  "Specifications" means: with respect to each Product, the specifications
for such Product as set forth in Exhibit C, as such specifications may be
amended by Chiron from time to time.

1.11.  "Technology" means: all inventions, discoveries, procedures, processes,
methods, data, information, results, trade secrets and know-how, whether
patentable or otherwise, owned by or licensed (with a right to sublicense) to
Chiron or any of its Affiliates as of the Agreement Date or any time during the
term of this Agreement relating to the manufacture of the Products and shall
include, without limitation, the Specifications.

                                                                               2

<PAGE>

ARTICLE 2 - MANUFACTURE OF PRODUCT

2.1.   SynCo shall manufacture and supply to Chiron such quantities of Products
       as Chiron may from time to time order in accordance with the terms of
       this Agreement.

2.2.   SynCo will manufacture the Products on a campaign basis, one campaign per
       Product per year, with a minimum of 8 batches per campaign.

       Attached as Exhibit D is Chiron's firm order for Products to be
       (delivered) in 2000. SynCo hereby accepts such order. Subsequent orders
       shall be by firm written purchase order submitted nine months in advance
       of the requested shipping date.

2.3.   SynCo shall promptly notify Chiron by phone and by facsimile if any firm
       purchase order submitted by Chiron cannot be filled within 15 days of the
       requested shipping date. In such a case, SynCo will discuss with Chiron
       the means for promptly eliminating the back order.

2.5.   SynCo shall ship in accordance with Chiron's shipping instructions, at
       Chiron's expense. Title and risk of loss with respect to each shipment
       shall pass to Chiron upon delivery of the Product to a common carrier at
       the Plant.

ARTICLE 3 - TRANSFER OF TECHNOLOGY AND MATERIAL.

3.1.   Chiron hereby grants to SynCo a non-exclusive, royalty free license under
       the Patents and to use the Technology to manufacture Product solely for
       Chiron in accordance with the terms and conditions of this Agreement.

3.2.   Chiron shall provide SynCo with the Specifications and all other relevant
       Technology for the purpose of enabling SynCo to perform its obligations
       under this Agreement.

3.3.   Chiron will furnish SynCo, free of charge, with the Material in
       sufficient quantities for the purpose of enabling SynCo to perform its
       obligations under this Agreement.  The Material will remain the exclusive
       property of Chiron. SynCo will not transfer the Material to any third
       party. The Material will be released by the QA officer of Chiron. SynCo
       will maintain records of usage of the Material, and will inform Chiron of
       needs for additional quantities in a timely manner, and return to Chiron
       any unused quantities of the Material upon request.

                                                                               3

<PAGE>

[LOGO]

ARTICLE 4 - REGULATORY AFFAIRS AND QUALITY ASSURANCE

4.1.   SynCo shall manufacture all Products supplied to Chiron hereunder in the
       Plant and shall not transfer Technology to, or manufacture Product at,
       any other location without the prior written consent of Chiron.

4.2.   SynCo shall and maintain adequate equipment, knowledge and experience and
       competent personnel to carry out satisfactorily its obligations under
       this Agreement.

4.3.   SynCo shall exercise all reasonable skill, care and diligence in the
       performance of its duties under this Agreement and shall carry out all
       responsibilities with recognized professional standards and the
       requirements of GMP. SynCo shall obtain and maintain all legally required
       permits in order to manufacture the Products in the Plant. SynCo shall
       inform Chiron of all permits filed and their status with respect to
       approval.

4.4.   SynCo shall not subcontract any part of its obligations under this
       Agreement to a third party without prior written approval by Chiron.

4.5.   Chiron will provide to SynCo the release tests to be performed on the
       Products and SynCo will perform such release testing in accordance with
       Chiron's written instructions.

4.6.   SynCo shall write and maintain all BPRs and all documentation relating to
       the manufacture of Product supplied hereunder in the English language.

4.7.   Subject to reasonable prior notice, Chiron's designated representatives
       may inspect those portions of the Plant used in the production of the
       Products for the purpose of determining compliance with GMP and the terms
       of this Agreement at reasonable times during the production campaign of
       the Products. SynCo will provide full cooperation for these inspections.

4.8.   SynCo's Quality Assurance unit shall review and approve all BPRs and
       shall investigate all deviations on such BPRs. This unit shall also
       ensure that the Plant and manufacturing operations are in compliance with
       GMP and with any other applicable law or regulation in effect during the
       time of manufacture of the Product. Within sixty days of completion of
       manufacture of each batch of Product, SynCo will supply Chiron with a
       "Certification of Compliance" for such batch stating that the BPRs and
       related documentation have been reviewed and found to be in GMP
       compliance.

4.9.   Chiron will have final responsibility for the release of each batch of
       Product manufactured by SynCo.

4.10.  SynCo will notify Chiron at least six (6) months in advance of any
       proposed modifications to the Plant, utilities, equipment or any other
       aspect of the manufacturing process for the Products. SynCo shall not
       make any such change without the prior written consent of Chiron, which
       consent Chiron may withhold in its reasonable discretion if the change
       have any impact on Chiron's Marketing Authorizations for any or all of
       the Products.

                                                                               4

<PAGE>

[LOGO]

4.11.  SynCo will retain manufacturing data, test records, and raw material
       samples as required to satisfy GMP. SynCo will provide Chiron, free of
       charge, with copies of all manufacturing data and test records, as well
       as copies of other documents resulting from work under this Agreement,
       required by Chiron for regulatory purposes. In the event of termination
       of the Agreement, all original manufacturing data, test records, samples
       and other materials required to satisfy GMP for the production of the
       Products will be delivered to Chiron promptly upon its request.

4.12.  SynCo will permit the Regulatory Authorities to conduct inspections
       relating to the manufacture of the Products and will cooperate fully in
       connection with such inspections. SynCo will notify Chiron promptly of
       any of such inspections and shall promptly inform Chiron of the results
       of such inspections.

ARTICLE 5 - WARRANTIES AND LIABILITY

5.1.   SynCo warrants that:

       a)     the Products will be manufactured, packed, stored and delivered in
              compliance with this Agreement and all applicable laws,
              regulations, and orders, including GMP; without limiting the
              generality of the foregoing, SynCo will obtain and maintain in
              effect all required governmental permits, licenses, and approvals
              applicable to the manufacture of the Products and shall produce
              the Products in accordance with all such permits, licenses,
              orders, applications and approvals;

       b)     the Material will be received and stored in accordance with all
              applicable laws, regulations and orders and in accordance with the
              relevant specifications;

       c)     on the date of delivery thereof, the Products will conform to the
              Specifications; and

       d)     it will not carry on activities in the Plant which could
              reasonably prevent the Products from being manufactured in
              accordance with all applicable laws, regulations, and orders,
              including GMP.

EXCEPT AS OTHERWISE EXPRESSLY PROVIDED HEREIN, SYNCO MAKES NO WARRANTIES EXPRESS
OR IMPLIED AND EXPRESSLY DISCLAIMS WARRANTIES OF FITNESS FOR A PARTICULAR
PURPOSE OR MERCHANTABILITY, AND SYNCO SHALL NOT BE LIABLE FOR INCIDENTAL OR
CONSEQUENTIAL DAMAGES IN ANY CASE OF NONCONFORMITY. NEITHER PARTY SHALL BE
LIABLE TO THE OTHER PARTY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING FROM
ANY ALLEGED OR ACTUAL BREACH OF THIS AGREEMENT.

                                                                              5

<PAGE>

[LOGO]

5.2.   SynCo shall promptly replace, free of charge, any defective or
       non-conforming Product supplied to Chiron, provided Chiron notifies SynCo
       in writing upon discovery of such defect or non-conformity within a
       period of sixty days after SynCo's Quality Assurance has approved the
       Product pursuant to paragraph 4.8, and provided Chiron allows SynCo to
       evaluate the claim and to test the said quantity of Product within a
       reasonable period of time, but not to exceed sixty days. Replacement of
       the Product by Synco pursuant to this paragraph 5.2 shall be the sole
       remedy of Chiron against SynCo for defective or non-conforming Product.

5.3.   If the Parties disagree whether such Product is defective or
       non-conforming, then the Product in dispute will be tested and further
       analyzed by a qualified independent testing laboratory reasonably
       acceptable to both Parties. Such laboratory's testing will determine,
       using representative samples, whether the quantity of the Product is
       defective or non-conforming with the Specifications. The resulting
       determination of the laboratory will be final and binding on SynCo and
       Chiron. SynCo will bear the cost of such testing if the testing
       demonstrates that the Product is defective or non-conforming and Chiron
       will bear the cost if the testing demonstrates the Product is neither
       defective nor non-conforming.

5.4.   Except to the extent subject to indemnification by Chiron pursuant to
       paragraph 5.5., SYNCO will indemnify, defend and hold harmless Chiron and
       its Affiliates from and against any and all losses, claims, damages or
       liabilities (including but not limited to reasonable attorney's fees)
       arising from or relating to (a) any breach by SynCo of its
       representations, warranties or covenants under this Agreement; or (b) any
       negligence or intentional wrongdoing of SynCo.

5.5.   Except to the extent subject to indemnification by SynCo pursuant to
       Section 5.4., Chiron will indemnify, defend and hold harmless SynCo and
       its Affiliates from and against any and all losses, claims, damages or
       liabilities (including but not limited to reasonable attorney's fees),
       arising from or relating to (a) any use, including clinical trials, or
       sale by Chiron or any third party of any Product supplied by Synco
       hereunder; (b) any allegation by any third party of infringement of its
       intellectual property rights by or the manufacture, use or sale of
       Products by Chiron or any of its Affiliates; (c) any breach by Chiron of
       its representations, warranties or covenants under this Agreement; or (d)
       any negligence or intentional wrongdoing of Chiron.

                                                                              6

<PAGE>

5.6.   Any person seeking indemnity pursuant to this section (the "Indemnified
       Party") shall notify the Party from whom indemnification is sought (the
       "Indemnifying Party") in writing promptly upon becoming aware of any
       claim, threatened claim, damage, loss, suit, proceeding or liability
       ("Claim") to which such indemnification may apply. Failure to provide
       such notice shall constitute a waiver of the Indemnifying Party's
       indemnity obligations hereunder if and to the extent the Indemnifying
       Party is materially damaged thereby. The Indemnifying Party shall have
       the right to assume and control the defense of the Claim at its own
       expense. If the right to assume and control the defense is exercised, the
       Indemnified Party shall have the right to participate in, but not
       control, such defense at its own expense and the Indemnify Party's
       indemnity obligations shall be deemed not to include attorneys' fees and
       litigation expenses incurred by the Indemnified Party after the
       assumption of the defense by the Indemnifying Party. If the Indemnifying
       Party does not assume the defense of the Claim, the Indemnified Party may
       defend the Claim; provided, that the Indemnified Party will not settle or
       compromise the Claim without consent of Indemnifying Party, which consent
       will not be unreasonably withheld. The Indemnified Party shall cooperate
       with Indemnifying Party and will make available to Indemnifying Party all
       pertinent information under the control of the Indemnified Party.

ARTICLE 6 - CONSIDERATIONS AND PAYMENTS

6.1.   As payment in full for Product supplied hereunder, Chiron shall pay to
       SynCo the fully burdened, fairly allocated cost to SynCo of manufacturing
       such Product, determined in accordance with the accounting methodologies
       to be agreed by the Parties promptly after the date of this Agreement and
       attached as an exhibit hereto. The Parties agree that the cost for dried
       purified meningitis C polysaccharides supplied hereunder during 2000 and
       2001 shall be as set forth in Exhibit A.

6.2.   SynCo shall invoice Chiron in Netherlands Guilders or Euro's. Payment
       terms to SynCo shall be thirty (30) days net from the date of invoice.

ARTICLE 7 - CONFIDENTIALITY AND INTELLECTUAL PROPERTY

A Party receiving Confidential Information from the other Party or developing
Confidential Information hereunder shall not disclose such Confidential
Information to any third party or otherwise for a period extending ten (10)
years following expiration or earlier termination of this Agreement, except as
follows:

(a)    to the extent such information is or becomes general public knowledge
       through no fault of the recipient Party; or

(b)    to the extent such information can be shown by contemporaneous
       documentation of the recipient Party to have been in its possession prior
       to receipt thereof hereunder; or

(c)    to the extent such information is received by the recipient Party from a
       third party without any breach of an obligation to the disclosing Party;
       or

                                                                              7
<PAGE>

(d)    to the extent required by law, by local authorities for regulatory
       purposes or is necessary to perform its obligations under this
       Agreement, in which case, the recipient Party may disclose the
       information if the recipient Party gives the other Party prior notice of
       such disclosure and an opportunity to comment upon the content of the
       disclosure.  However, SynCo shall have the right, at all times and
       without the obligation to give notice to Chiron, to use information
       related to its Plant for its own business purposes and Chiron shall
       have the right, at all times and without the obligation to give notice
       to SynCo, to use the information related to the Vaccines for its own
       business purposes.

For the avoidance of doubt:  It is understood that SynCo purchased the Plant and
certain related equipment, including computers and other information technology
systems, from an Affiliate of Chiron, and that prior to such purchase the Plant
and equipment were utilized by Chiron and its Affiliates for the manufacture of
Products.  It is further understood that certain employees of SynCo formerly
were employees of an Affiliate of Chiron and were engaged directly or indirectly
in the manufacture of Products.  Notwithstanding anything to the contrary
contained herein, and in particularly notwithstanding paragraph (b) above, all
information relating the Specifications,  Technology or manufacture of the
Products which exists as of the date of this Agreement shall be owned solely and
exclusively by Chiron and shall not be disclosed by SynCo at any time during the
term of this Agreement or for a period of ten years following the expiration or
earlier termination of this Agreement.

Each Party shall use Confidential Information received from the other Party
solely for the purposes of this Agreement and for no other purpose whatsoever.

ARTICLE 8. - TERM OF AGREEMENT

The term of this Agreement shall commence as of the Date of Agreement, and will
continue until JANUARY 1, 2002 or terminated by any party upon six (6) months
prior written notice to the other party.  Termination of this agreement will not
relieve Chiron of its obligations to pay SynCo for Product previously supplied
hereunder and for commitments which arise directly out of firm purchase orders
for Products and which cannot reasonably be canceled or otherwise put to use.

ARTICLE 9 - ADDITIONAL TERMS

9.1.   FORCE MAJEURE.  A Party shall not be held liable to the other for any
       delay in performance or non performance of that Party directly or
       indirectly caused by reason of force majeure including, but not limited
       to, industrial disputes, strike, lockouts, riots, mobs, fires, floods,
       or other natural disasters, wars declared or undeclared, civil strife,
       embargo, lack or failure of transport facilities, currency restrictions,
       or events caused by reason of laws, regulations or orders by any
       government, governmental agency or instrumentality or by any other
       supervening circumstances beyond the control of either Party.  Provided,
       however, that the Party affected shall: give prompt written notice to the
       other Party of the date of commencement of the force majeure, the nature
       thereof, and expected duration; and shall use its best efforts to avoid
       or remove the force majeure to the extent it is able to do so; and shall
       make up, continue on and complete performance when such cause is removed
       to the extent it is able to do so.  Either Party has the right to
       terminate the Agreement with immediate effect and without any liability,
       upon written notice to the other Party, should the force majeure continue
       after three months (3) following the first notification.

                                                                              8
<PAGE>

9.2.   NON-WAIVER. The failure by any Party at any time to enforce any of the
       terms or provisions or conditions of this Agreement or exercise any
       right hereunder shall not constitute a waiver of the same or affect the
       validity of this Agreement or any part hereof, or that Party's rights
       thereafter to enforce or exercise the same. No waiver by a Party shall
       be valid or binding, except if in writing and signed by a duly
       authorized representative of the waiving Party.

9.3.   SEVERABILITY. In case one or more of the provisions contained in this
       Agreement shall, for any reason, be held invalid, illegal or
       unenforceable in any respect, such holding shall not affect any other
       provisions of this Agreement, but this Agreement shall be construed by
       limiting such provision to such extent as would nearly as possible
       reflect the intent, purpose and economic effect of such provision, or,
       if such is not possible, by deleting such provision from this Agreement,
       provided that the remaining provisions reflect the intent of the
       Parties, as evidenced by this Agreement as a whole.

9.4.   CAPTIONS. All titles and captions in this Agreement are for convenience
       only and shall not affect its interpretation.

9.5.   LAW AND ARBITRATION. This Agreement shall be governed, construed and
       interpreted by the law of the Netherlands. The Parties agree that all
       disputes between them arising out of or relating to this Agreement shall
       be settled by arbitration in accordance with the Rules of Conciliation
       and Arbitration of the International Chamber of Commerce by three
       arbitrators appointed in accordance with such Rules. The arbitration
       proceedings shall take place in Amsterdam, The Netherlands if initiated
       by Chiron and in Milan, Italy if initiated by SynCo and shall be
       conducted in the English language. Judgment on the award may be issued
       by and enforced by any court of competent jurisdiction.

9.6.   ENTIRE UNDERSTANDING. This Agreement (including appendices) is the
       entire understanding and agreement between the Parties relating to the
       subject matter hereof and supersedes (except as provided herein) any and
       all prior arrangements, understandings, and agreements between the
       Parties whether written or oral relating thereto. No amendments,
       changes, or modifications of the terms of this Agreement shall be valid
       or binding unless made in writing and signed by the duly authorized
       representatives of each Party.

9.7.   INDEPENDENT STATUS OF PARTIES. Each Party is an independent party acting
       in its own name and for its own account. Neither Party has any authority
       to act as an agent or representative of the other, or to contract in the
       name of, or create or assume any obligation against, or otherwise
       legally bind, the other Party in any way for any purpose, unless agreed
       separately in writing. All costs and expenses connected with each
       Party's activities and performance under this Agreement unless otherwise
       separately agreed or provided for in this Agreement are to be borne
       solely by the Party incurring such costs and expenses.

                                                                              9

<PAGE>

[LOGO]

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their duly authorized representatives:

Chiron S.p.A.                             SynCo Bio Partners B.V.

/s/ Dr. Gabriele Brusa                    /s/ Dr. Mic N. Hamers

Dr. Gabriele Brusa                        Dr. Mic N. Hamers
Chief Executive Officer                   Managing Director

                                                                             10

<PAGE>

[LOGO]

                                      EXHIBIT A

                               COST OF CERTAIN PRODUCT

The price per batch of dried purified MenC polysaccharides amounts to two
hundred and ninety four thousand (294,000) Dutch Guilders excluding VAT.

                                                                             11

<PAGE>

                                      EXHIBIT B

                                   LIST OF PRODUCTS

HIB
MEN C
CRM197
MEN A

[LOGO]

                                                                             12

<PAGE>

[LOGO]

                                      EXHIBIT C

                       OPERATING PROCEDURES AND SPECIFICATIONS

BATCH PRODUCTION RECORDS

MF-BPR-MEC-2850      Preparation of Inoculum for MEC production
MF-BPR-MEC-2900      Production of MEC on 1500 liter scale; Fermentation
MF-BPR-MEC-2950      Production of MEC on 1500 liter scale; Primary Recovery
MF-BPR-MEC-3000      Extraction of MenC Polysaccharides out of CTAB Wet Paste
MF-BPR-MEC-3005      Q-Sepharose XL Ion Exchange Chromatography for the
                     purification of MenC Polysaccharides
MF-BPR-MEC-3010      Ultrafiltration and precipitation of Men-C polysaccharide

COMPONENT PREPARATION RECORDS (ONE-BATCH RELATED)

MF-CPR-MEN-0001      Preparation of sterile MEN base medium in shake flasks
MF-CPR-MEN-0002      Preparation of 0.2 micron filtered Fermentation Supplements
MF-CPR-MEN-0003      Materials for MEC Fermentation and Primary Recovery (1500
                     I scale)
MF-CPR-MEN-0004      Preparation of 0.2 Tm filtered Inoculum Supplements

MF-CPR-XXX-3940      Buffer VA; 0.4 M NaCl in 20 mM TrisHCl, pH 7.75
MF-CPR-XXX-3941      Buffer VB; 0.2 M NaCl in 38% Ethanol and 10 mM TrisHCl, pH
                     7.5
MF-CPR-XXX-3942      Buffer VC; 1 M NaCl in 38% Ethanol and 10 mM TrisHCl, pH
                     7.5
MF-CPR-XXX-3943      Buffer VD; 2 M NaCl in 38% Ethanol and 100 mM TrisHCl, pH
                     7.5
MF-CPR-XXX-3944      Buffer VE; 20 mM CaCl(2) in 38% Ethanol

MF-CPR-XXX-3930      2 M Calcium Chloride
MF-CPR-XXX-3959      20% (v/v) Ethanol
MF-CPR-XXX-3973      1.0 M Sodium Hydroxide
MF-CPR-XXX-3911      4.2 M Acetic Acid Solution

COMPONENT PREPARATION RECORDS (MULTIPLE-BATCH RELATED)

MF-CPR-XXX-0001      Preparation of Ultrafiltrate Yeast Extract solution (10%
                     w/v)
MF-CPR-XXX-2024      Sterile 50% (w/v) Glucose

13

<PAGE>

[LOGO]

                                      EXHIBIT C

                       OPERATING PROCEDURES AND SPECIFICATIONS
                                       (CONT'D)

CLEANING CPR'S (ONE-BATCH RELATED)

MF-CPR-XPT-2030      Cleaning the 1000 I Process Tank
MF-CPR-XPT-2050      Cleaning the 4000 I Process Tank
MF-CPR-XFR-2002      Cleaning Procedure for the 1500 I Fermentation System
MF-CPR-XTL-2080      Cleaning the Transfer Loop
MF-CPR-XCT-2100      Cleaning the Recovery Skid
MF-CPR-XCT-2580      Cleaning the Westfalia CSA-8 Centrifuge
MF-CPR-XUF-2220      Cleaning and Testing of Millipore Ultrafiltration System

                                                                             14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]